13 results
8-K
EX-99.1
ATHA
Athira Pharma Inc
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
risk
Updated study well powered for primary endpoint with addition of fewer than 150 patients
Company targets completion of enrollment in mid-2023
DFAN14A
EX-99.1
ATHA
Athira Pharma Inc
27 Apr 22
Additional proxy materials by non-management
2:39pm
of two Perceptive-sponsored SPACs that reportedly are seeking acquisition targets. But the SPAC market has collapsed. It is totally unacceptable … and a dereliction of his fiduciary duties for Mr. Edelman to be distracted by efforts to save his hedge fund and/or searches for SPAC targets rather than
10-K
2020 FY
ATHA
Athira Pharma Inc
25 Mar 21
Annual report
12:00am
molecular targets relevant to nervous system disorders.
Additional Development Opportunities
Our Neuropsychiatric Program (ATH-1019 / ATH‑1020)
We
424B4
yinr8fdijcwlzyn0q
21 Jan 21
Prospectus supplement with pricing info
12:00am
DRS
cnyy7ke
6 Jan 21
Draft registration statement
12:00am
424B4
xbs3puzfh y8v9wi
18 Sep 20
Prospectus supplement with pricing info
4:05pm
S-1
mqckvh
26 Aug 20
IPO registration
5:25pm
DRS
p27btyx0
24 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next